Akers Biosciences Receivables

Akers Biosciences (AKER) currently reports a receivables of $43K as of December 2020. That compares with $43K in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Akers Biosciences's receivables history and peer comparisons.

Akers Biosciences's receivables was unchanged from $43K to $43K — essentially flat versus a year earlier (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akers Biosciences reported $43K in receivables as of December 2020. That compares with $43K in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $43K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akers Biosciences, and consider following AKER for alerts when major investors trade the stock.

Akers Biosciences is classified in the Healthcare sector. On receivables, it currently shows $43K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKER with unrelated industries.